Endocrine disorders in mitochondrial disease by Schaefer AM et al.
 Newcastle University ePrints 
 
Schaefer AM, Walker M, Turnbull DM, Taylor RW. 
Endocrine disorders in mitochondrial disease.  
Molecular and Cellular Endocrinology 2013, 379(1-2), 2-11. 
 
Copyright: 
Copyright © 2013 The Authors. Published by Elsevier Ireland Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution-
NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and 
reproduction in any medium, provided the original author and source are credited. 
Link to published article: 
http://dx.doi.org/10.1016/j.mce.2013.06.004 
 
Date deposited:  1st December 2014 
 
 
 
This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License 
 
 ePrints – Newcastle University ePrints 
http://eprint.ncl.ac.uk 
 
Molecular and Cellular Endocrinology 379 (2013) 2–11Contents lists available at ScienceDirect
Molecular and Cellular Endocrinology
journal homepage: www.elsevier .com/locate /mceReviewEndocrine disorders in mitochondrial disease1
1
1
1
1
1
0303-7207  2013 The Authors. Published by Elsevier Ireland Ltd.
http://dx.doi.org/10.1016/j.mce.2013.06.004
⇑ Corresponding authors. Address: Wellcome Trust Centre for Mitochondrial Research, Institute for Ageing and Health, The Medical School, Newcastle Un
Framlington Place, Newcastle upon Tyne NE2 4HH, UK. Tel.: +44 1912223685.
E-mail addresses: andrew.schaefer@nuth.nhs.uk (A.M. Schaefer), robert.taylor@ncl.ac.uk (R.W. Taylor).
Open access under CC BY-NC-ND license.Andrew M. Schaefer a,⇑, Mark Walker b, Douglass M. Turnbull a, Robert W. Taylor a,⇑
aWellcome Trust Centre for Mitochondrial Research, Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK
b Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UKa r t i c l e i n f o
Article history:
Available online 13 June 2013
Keywords:
Mitochondrial disease
Endocrine
mtDNA
Diabetes
m.3243A > Ga b s t r a c t
Endocrine dysfunction in mitochondrial disease is commonplace, but predominantly restricted to disease
of the endocrine pancreas resulting in diabetes mellitus. Other endocrine manifestations occur, but are
relatively rare by comparison. In mitochondrial disease, neuromuscular symptoms often dominate the
clinical phenotype, but it is of paramount importance to appreciate the multi-system nature of the dis-
ease, of which endocrine dysfunction may be a part. The numerous phenotypes attributable to pathogenic
mutations in both the mitochondrial (mtDNA) and nuclear DNA creates a complex and heterogeneous
catalogue of disease which can be difficult to navigate for novices and experts alike. In this article we pro-
vide an overview of the endocrine disorders associated with mitochondrial disease, the way in which the
underlying mitochondrial disorder influences the clinical presentation, and how these factors influence
subsequent management.
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The termmitochondrial disease refers to a heterogeneous group
of multi-system disorders characterised by mitochondrial respira-
tory chain deficiency in which neurological involvement is often
prominent (McFarland et al., 2010; Ylikallio and Suomalainen,
2012). Numerous distinct genotypes give rise to varied and over-
lapping phenotypes. Endocrine dysfunction is a frequent feature,
predominantly due to the prevalence of diabetes mellitus associ-
ated with the m.3243A > G mutation, the most common hetero-
plasmic mtDNA mutation associated with human disease
(Schaefer et al., 2008). Other forms of endocrine disease are de-
scribed less frequently, occurring in numerous mitochondrial dis-
orders due to either mutations within mtDNA or associated with
nuclear-driven disorders of mtDNA maintenance. For many muta-
tions, reports of endocrine disease are so rare as to challenge the
hypothesis that they are mediated by defects of oxidative phos-
phorylation at all, and merely represent the background preva-
lence of endocrine disease in a well studied population. There is
a danger that associations based on single case reports (sometimes
dating back 20 years and beyond) are repeatedly cited in reviews
such as this, perpetuating an unproven connection with mitochon-
drial disease. Analysis of large patient cohorts are likely to be key,
and while this dilemma may not be readily resolved for rare muta-
tions, it should be feasible to answer the question in more preva-
lent disorders. As ever, further studies are needed in this area.
This review summarises the range of endocrine involvement in
mitochondrial disease and the genotypes and phenotypes in which
these occur. We offer insights from a specialist mitochondrial clinic
as to the use of pattern recognition and pedigree analysis in the
diagnosis and subsequent management of these complex patients
and their families.2. Mitochondrial biochemistry and genetics
Mitochondria are essential organelles, present in all nucleated
mammalian cells, whose main role is to produce ATP by the pro-
cess of oxidative phosphorylation (OXPHOS). The OXPHOS machin-
ery is made up of 90 different polypeptides, organised into five
transmembrane complexes. The oxidation of foodstuffs generates
electrons which are shuttled to oxygen along the first four respira-
tory chain complexes whilst protons are pumped across the inner
mitochondrial membrane from the matrix to the intermembrane
space forming an electrochemical gradient which is harnessed by
ATP synthase, to phosphorylate ADP to form ATP. Mitochondrial
function and biosynthesis is under the dual genetic control of both
the mitochondrial genome – encoding just 13 proteins and 37 gene
products in total and the nuclear genome, which encodes for some
1400–1500mitochondrial proteins. Whilst mutations within either
DNA molecule can cause a respiratory chain defect, the unique ge-
netic rules which govern the behaviour of the mitochondrial gen-
ome provide some insight into the phenotypic heterogeneity
which particularly characterise mtDNA disorders.
Several recent reviews have detailed the importance of mtDNA
mutations in human disease (Greaves et al., 2012; Schon et al.,
2012). The mitochondrial genome is a highly-organised, 16.6 kb
circular genome whose complete sequence was published over
30 years ago (Anderson et al., 1981), prompting the discovery of
the first pathogenic mutations in 1988 involving either mtDNA
rearrangements or deletions (Holt et al., 1988) or point mutations
(Wallace et al., 1988). Strictly inherited through the maternal line-
age, it is present within cells in multiple copies, reflecting the de-
mand for OXPHOS-derived energy of that particular tissue. When
all mtDNA molecules within a cell are identical, a situation known
as homoplasmy prevails. The presence of two or moremitochondrial genotypes, as typified in many pathogenic mtDNA
mutations, results in a situation known as heteroplasmy in which
the ratio of wild-type to mutated mtDNA determines the onset of
clinical symptoms. A minimum critical proportion of mutated
mtDNAmolecules are required before biochemical deficiency man-
ifests as a clinical phenotype, with this threshold level varying for
different mutations and tissues. Functional consequences are most
commonly seen in post-mitotic tissues with high energy require-
ments (e.g. muscle, brain, and heart) but almost any tissue can
be involved, including the endocrine organs. Individual mtDNA
mutations often dictate the pattern of involvement, with some
more strongly associated with endocrine disease than others.
The exact prevalence of mtDNA disease has proven difficult to
define but estimates from our cohort in the North East of England
suggest that mtDNA mutations of all types cause a point preva-
lence of disease in adults of 9.2/100,000 population, with a further
16.5/100,000 at risk of developing disease due to carrier status at
any one time (Schaefer et al., 2008). Birth prevalence studies have
reported mutation frequencies of 0.14% for some common mtDNA
mutations such as the m.3243A > G mutation (Elliott et al., 2008),
although most individuals will not manifest clinical disease as
the majority of mutations are present at subthreshold levels.
Several other factors are important in understanding the behav-
iour of pathogenic, heteroplasmic mtDNA mutations in relation to
clinical disease. During mitotic cell division, mitochondria are ran-
domly segregated to daughter cells and as such the proportion of
mutated mtDNA can shift in the presence of heteroplasmy. The
observation of a rapid segregation in mammalian heteroplasmic
mtDNA genotypes between generations is evidence for the exis-
tence of a mtDNA developmental genetic bottleneck; this involves
a marked reduction in mtDNA copy number in the germline fol-
lowed by the replication of a subgroup of mtDNA molecules during
oogenesis although the precise mechanism remains to be fully
determined (Cao et al., 2007; Cree et al., 2008; Wai et al., 2008).
In addition to primary mtDNA mutations, mutations in nuclear
genes involved in mtDNA replication or repair (often termed
mtDNA maintenance) can give rise to secondary qualitative or
quantitative mtDNA abnormalities. Mutations in nuclear genes
implicated in many other mitochondrial processes including struc-
tural respiratory chain components, mitochondrial nucleotide sal-
vage and synthesis and mitochondrial translation are increasingly
being described with the advent of next-generation screening
and mito-exome sequencing (Ylikallio and Suomalainen, 2012;
Calvo et al., 2012) highlighting that mitochondrial disease may
be inherited as Mendelian traits, with autosomal dominant (ad-),
autosomal recessive (ar-), and even X-linked forms.3. Investigation of mitochondrial disease
The complex interplay between mtDNA heteroplasmy and phe-
notypic expression, and the potential contribution from both nu-
clear and mitochondrial genomes, makes mitochondrial disease
one of the most difficult inherited disorders to diagnose. The lack
of curative treatments for these conditions places greater emphasis
on accurate genetic advice and counselling, which should be
undertaken by a specialist with experience in this area.
Our own algorithms for the laboratory investigation of mito-
chondrial disease have been published extensively (Taylor et al.,
2004; Tuppen et al., 2010; McFarland et al., 2010) and rely on
information from the clinical phenotype and functional data (his-
tochemistry and biochemistry) to guide genetic studies of both
mtDNA and nuclear genes. Some common mtDNA mutations can
be reliably detected and screened in blood, but there is a potential
for false-negative results in some mutations. This possibility
should be highlighted in the case of the m.3243A > G mutation,
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sumedmitochondrial disease and is associatedwith numerous clin-
ical syndromes includingmitochondrial encephalomyopathy, lactic
acidosis and stroke-like episodes (MELAS), maternally-inherited
diabetes and deafness (MIDD), and, less commonly, myoclonic epi-
lepsywith ragged red fibres (MERRF). Levels of thismutationwithin
leucocytes have been shown to decrease by1.4% per year (Rahman
et al., 2001) and we have several patients within our own cohort in
whom the m.3243A > G mutation would not have been detected
fromblood alone. The risk of false negative resultsmay be decreased
by screening alternativemtDNAsources including urinary epithelial
cells (McDonnell et al., 2004; Blackwood et al., 2010). For some
mutations, notably m.3243A > G, the level in this tissue correlates
wellwith clinical severity (Whittaker et al., 2009).Muscle biopsy re-
mains thegold standard, yet in aminorityof patients a completebio-
chemical analysis of muscle tissue can be normal, whilst the
demonstration of histological and histochemical hallmarks of mito-
chondrial disease still require additional genetic testing. A prag-
matic strategy for genetic testing is often best derived from liaison
with a specialist mitochondrial centre. Pattern recognition is key
and specific phenotypes may raise an otherwise rare mutation to
the forefront of the process (e.g. Alper syndrome due to reces-
sively-inherited POLG gene mutations). Pathogenic mtDNA muta-
tions and mtDNA rearrangements are now relatively easy to
exclude where a muscle biopsy has already been performed, and
in many cases should be screened in both adults and children prior
to nuclear genetic testing, a processwhichmay require investigating
numerous candidate genes. This once laborious process is being rev-
olutionisedby thenext-generation sequencing revolution leading to
the identification ofmanynewmitochondrial disease genes over the
last 2–3 years.
4. Diabetes mellitus
Diabetes mellitus is well recognised within mitochondrial phe-
notypes and is the most common endocrine manifestation of dis-
ease. This is mainly because of its association with the MIDD
phenotype which is common in patients carrying the
m.3243A > G MTTL1 mutation (van den Ouweland et al., 1992;
Whittaker et al., 2007). Diabetes is also a common condition in
its own right, estimated to affect 4.45% of the UK population. It is
not surprising, therefore, that it is common for mitochondrial dia-
betes to be misdiagnosed, even in the presence of other features
that may provide clues as to the underlying genetic disease. The
importance of pattern recognition in diagnosis is discussed subse-
quently, but for the m.3243A > G mutation, the cardinal features
are of maternal inheritance and pre-senile sensorineural hearing
loss. Prevalence of the m.3243A > G mutation in unselected dia-
betic populations varies between 0% and 2.8% from the larger stud-
ies (Vionnet et al., 1993; Katagiri et al., 1994; Otabe et al., 1994;
t’Hart et al., 1994; Kishimoto et al., 1995; Odawara et al., 1995;
Uchigata et al., 1996; Abad et al., 1997; Saker et al., 1997; Tsukuda
et al., 1997; Holmes-Walker et al., 1998; Lehto et al., 1999; Matsu-
ura et al., 1999; Malecki et al., 2001; Ohkubo et al., 2001; Suzuki
et al., 2003; Maassen et al., 2004; Murphy et al., 2008). Deafness,
neuromuscular disease, end stage renal disease, and a maternal
family history all increase the likelihood of mitochondrial disease
(t’Hart et al., 1994; Majamaa et al., 1997; Newkirk et al., 1997;
Smith et al., 1999; Ng et al, 2000; Iwasaki et al., 2001; Klemm
et al., 2001; Suzuki et al., 2003; Murphy et al., 2008). There are sev-
eral other mtDNA mutations recognised to consistently express a
phenotype which includes diabetes. These include the
m.14709T > C mutation (Hanna et al., 1995; Vialettes et al., 1997;
Choo-Kang et al., 2002) which has been reported to be homoplas-
mic in some patients (McFarland et al., 2004) and may cause up to
13% of mitochondrial diabetes in the North East of England (Whit-taker et al., 2007). The m.8296A > GMTTK gene mutation was iden-
tified in 0.9% unrelated Japanese patients with diabetes, and 2.3%
with diabetes and deafness (Kameoka et al., 1998). The
m.14577T > C MTND6 mutation, associated with isolated complex
I deficiency, was found in 0.79% unrelated Japanese patients with
diabetes (Tawata et al., 2000).
Other mtDNA point mutations have been described but appear
much rarer. The m.12258T > C MTTS2 gene mutation has been
associated with diabetes (Lynn et al., 1998) but in other mater-
nally-related kindreds, diabetes has been notably absent (Man-
sergh et al., 1999). The m.3271T > C MTTL1 mutation has been
associated with the MIDD, MELAS and MERRF phenotypes (Goto
et al., 1991; Suzuki et al., 1996; Tsukuda et al., 1997), whilst the
m.3264T > C MTTL1 mutation was observed with MIDD, the pro-
band having chronic progressive external ophthalmoplegia (CPEO)
and cervical lipomata in addition (Suzuki et al., 1997).
In a number of mtDNA mutations, diabetes is not considered
part of the established phenotype, despite rare reports. This group
includes the m.8344A > G mutation causing myoclonic epilepsy
and ragged-red fibres (MERRF) (Austin et al., 1998; Whittaker
et al., 2007), the m.8993T > C mutation which is associated with
the maternally-inherited Leigh syndrome (MILS) phenotype (Naga-
shima et al., 1999) and mtDNA mutations causing Leber hereditary
optic atrophy (LHON) (Newman et al., 1991; Du Bois and Feldon,
1992; Pilz et al., 1994; Cole and Dutton, 2000).
Single, large-scale mtDNA deletions have been reported to
cause diabetes in 11% (6 of 55 patients) of well-defined, clinical co-
horts of patients with CPEO and Kearns Sayre Syndrome (KSS)
(Whittaker et al., 2007). An earlier paper reviewing existing case
reports of KSS reported the prevalence of diabetes to be 13% (29
of 226) but not all cases had genetic confirmation of a deleted
mitochondrial genome (Harvey and Barnett, 1992). A single report
documents a child who presented with insulin dependent diabetes
mellitus (IDDM) and adrenal insufficiency prior to the develop-
ment of ophthalmoplegia and a diagnosis of KSS (Mohri et al.,
1998). Rarely, mtDNA deletions have been reported to cause IDDM
in Pearson’s Syndrome, but on the whole pancreatic failure is usu-
ally exocrine (Superti-Furga et al., 1993; Williams et al., 2012).
Other mtDNA rearrangements, notably maternally-transmitted
duplications of the mitochondrial genome, have been reported in
association with diabetes (Rötig et al., 1992; Ballinger et al., 1994).
The recognised spectrum of disease due to mutations within
nuclear maintenance genes is still expanding, but diabetes has
been reported in 11% of adult CPEO phenotypes with ar-POLG
mutations (Horvath et al., 2006). In adult-onset PEO due to RRM2B
mutations, only 4.5% (1 of 22 in this cohort) had diabetes (Pit-
ceathly et al., 2012). Late-onset type-2 diabetes is rare (3 of 83)
in OPA1 pedigrees (Yu-Wai-Man et al., 2010) and is not a feature
of ar-PEO1 (Twinkle) gene mutations (Lönnqvist et al., 2009).
There are other documentedmutations associatedwith diabetes,
most of which are sufficiently rare as an individual entity as to not
warrant lengthydiscussion in this review. The role of the 16,189var-
iant in causing diabetes remains unclear (Poulton et al., 2002; Das
et al., 2007) but the numerous reports of pathogenic mtDNA muta-
tions associated with a diabetic phenotype does highlight that the
endocrine pancreas is particularly susceptible tomitochondrial dys-
function. Combinedwith involvementof other tissues this is a useful
pointer towards mitochondrial disease as a diagnosis.5. Mitochondrial diabetes
5.1. Pattern recognition
Faced with the fact that mitochondrial diabetes is relatively
scarce in the general diabetes clinic, it is helpful to have a
A.M. Schaefer et al. /Molecular and Cellular Endocrinology 379 (2013) 2–11 5structured approach to help decide which patients should be con-
sidered for mtDNA mutation screening.
The text book description of the short, deaf patient with diabe-
tes is in reality a rare occurrence and probably represents the tip of
the iceberg in terms of mitochondrial diabetes. Historically these
descriptions referred to patients with severe disease due to either
m.3243A > G or KSS. These ‘textbook’ patients are usually younger
and with low Body Mass Index (BMI) as well as height. This prob-
ably reflects more extensive multisystem involvement with higher
levels of heteroplasmy in most tissues, and rarely will the diabetic
clinic be the first medical encounter for these patients. The same is
true of recessive forms of mitochondrial disease, where clear mul-
tisystem disease is likely to have raised the question of mitochon-
drial disease already.
There are differences betweenmitochondrial diabetes and type-
2 diabetes, and these will be discussed in the subsequent para-
graphs. Within the real world however, of busy clinics filled with
common disorders, a physician who diagnoses mitochondrial dia-
betes without additional clues should consider themselves partic-
ularly astute. A maternal family history or sensorineural deafness
should raise suspicion. While deafness in old age or a family his-
tory of type-2 diabetes is not uncommon, pre-senile sensorineural
deafness is unusual, and especially so if combined with diabetes
and a maternal history of either disorder, and/or other conditions
such as cardiomyopathy, epilepsy, ptosis or unusual sounding
strokes. Each additional feature adds weight to the growing suspi-
cion of a mitochondrial disorder. Asymptomatic individuals and
apparently ‘skipped’ generations within a pedigree should not les-
sen the suspicion as this is a common observation in mtDNAmuta-
tions due to carriers with low levels of heteroplasmy. In our
mitochondrial cohort in the North East of England, 82/138 (59%)
individuals within m.3243A > G pedigrees showed no signs of dis-
ease at the time of assessment, despite being at risk by virtue of
maternal inheritance patterns; 82% of relatives opting for predic-
tive testing subsequently test positive (Schaefer et al., 2008). This
frequency remains constant whether testing 1st, 2nd or 3rd degree
relatives. 30% of these patients go on to develop typical features
associated with the m.3243A > G mutation over the next 5 years
(Schaefer et al., 2008) and this figure continues to rise with subse-
quent follow up (Schaefer and colleagues, unpublished data).
There is conflicting evidence regarding the predictive value of a
maternal family history alone (Ng et al., 2000; Choo-Kang et al.,
2002). As pure diabetic phenotypes are extremely rare in mtDNA
disease, it is probably true that a family history of diabetes alone
is unlikely to suggest mitochondrial disease (Choo-Kang et al.,
2002). The detail of the pedigree analysis is all important, however,
as often enquiry is restricted to the scope of the clinic being at-
tended, whether diabetic or neurological; and important associa-
tions may be easily overlooked. Most mitochondrial patients in
the diabetic clinic will have a more subtle presentation, but deaf-
ness is usually present when diabetes is diagnosed (Suzuki et al.,
1994; Guillausseau et al., 2001; Uimonen et al., 2001). An audio-
gram can confirm its presence if it has not been formally assessed.
A variable number of additional features (such as ptosis, proximal
myopathy, cerebellar ataxia, axonal sensorimotor neuropathy, gas-
trointestinal dysmotility and pigmentary retinopathy) are com-
monly present, but are often subtle and may be missed if not
looked for specifically. Regular ophthalmologic assessments in dia-
betic patients afford an opportunity to identify pigmentary retin-
opathies, but the pick-up rate is increased if the ophthalmologist
is aware of the clinical suspicion.
5.2. Age-at-onset
Mitochondrial diabetes usually presents insidiously, much like
type-2 diabetes. When due to the m.3243A > G mutation it canpresent at virtually any age, but typically develops in mid-life with
an average age-at-onset of 37 or 38 years (Guillausseau et al.,
2004; Whittaker et al., 2007). Only rarely does the diabetes present
in childhood (Guillausseau et al., 2004).
5.3. Insulin requirements
Mitochondrial diabetes is felt to occur as a result of insulin defi-
ciency (Reardon et al., 1992; Oka et al., 1993; Kadowaki et al.,
1993; Kadowaki et al., 1994; Katagiri et al., 1994; Walker et al.,
1995a) rather than insulin resistance (Walker et al., 1995b; Velho
et al., 1996), but in some patients both mechanisms may play a
part (Szendroedi et al., 2009). Approximately 20% of cases of mito-
chondrial diabetes may present acutely, with 8% suffering from
ketoacidosis (Guillausseau et al., 2001; Guillausseau et al., 2004;
Maassen et al., 2004), but only 13% of diabetic patients carrying
the m.3243A > G mutation require insulin at diagnosis (Whittaker
et al., 2007). Of the remaining 87% of patients, mitochondrial dia-
betes develops insidiously but usually progresses rapidly to insulin
requirement, another observation unusual in type-2 diabetes;
45.2% of such patients made this transition (Whittaker et al.,
2007). Average transition rates to insulin requirement range be-
tween 2 and 4.2 years (Guillausseau et al., 2001; Guillausseau
et al., 2004; Maassen et al., 2004; Whittaker et al., 2007). Those pa-
tients assessed by Whittaker and colleagues were under stringent
review in a specialist mitochondrial clinic, and early diagnosis of
diabetes through screening programmes may explain the longer
transition times as compared to other studies.
5.4. Body Mass Index (BMI)
One of the clues that appears consistent in mitochondrial diabe-
tes is the tendency for patients to have a lower than average BMI
(Guillausseau et al., 2004; Whittaker et al., 2007), an unusual
observation in typical type-2 diabetes. Lower BMI tends to corre-
late with earlier onset of diabetes, earlier insulin requirements,
and higher HbA1C measurements (Guillausseau et al., 2004). This
probably reflects a higher overall disease burden as lower BMI
tends to be associated with an earlier onset of disease and a more
severe phenotype in general (Schaefer and colleagues, unpublished
data).
5.5. End organ disease
Although neuropathy and renal disease can occur indepen-
dently of diabetes in the m.3243A > G mutation, each complication
has been reported to be significantly more prevalent in those pa-
tients with diabetes. In addition, patients with diabetic retinopathy
or renal impairment demonstrated higher HbA1C levels than those
who did not (Whittaker et al., 2007). This suggests that poor gly-
caemic control plays a major role in their pathogenesis. The risk
of neuropathy and renal disease in the same diabetic
m.3243A > G cohort was reported to be higher than in other forms
of either type-1 or type-2 diabetes, which implies that pre-existent
mitochondrial dysfunction within these end organs predisposes to
the microvascular complications of diabetes (Whittaker et al.,
2007). Prevalence rates for these complications exceed those re-
ported in the United Kingdom Prospective Diabetes Study in
type-2 diabetes or the DCCT in type-1 diabetes (The Diabetes Con-
trol and Complications Trial Research Group, 1993; Adler et al.,
2003). Interestingly, several studies have reported lower rates of
diabetic retinopathy in MIDD (Holmes-Walker et al., 1998; Massin
et al., 1999; Smith et al., 1999; Latvala et al., 2002) than would nor-
mally be expected in type-1 or type-2 diabetes (Misra et al., 2009;
Thomas et al., 2012). The same appears true of cataracts. This has
been proposed to be due to reduced glucose metabolism by the
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tolerance also appears to increase the clinical expression of the pig-
mentary retinopathy typically seen in patients with the
m.3243A > G mutation. 15 of 23 patients from MIDD kindreds
had evidence of a pigmentary retinopathy, 13 of which had evi-
dence of glucose intolerance (Holmes-Walker et al., 1998).
m.3243A > G heteroplasmy levels from muscle-derived mtDNA
did not correlate with the age of onset of diabetes, whilst hetero-
plasmy levels from blood or muscle did not correlate with the time
taken to progress to insulin requirement, or the risk of diabetic
complications; an inverse correlation between age of diabetic on-
set and heteroplasmy level in blood derived mtDNA was reported
(Whittaker et al., 2007), but the true significance of this was diffi-
cult to predict as heteroplasmy levels in blood are known to de-
crease year by year in patients carrying the m.3243A > G
mutation due to replicative disadvantage (Rahman et al., 2001). A
subsequent multicentre study found that correcting for age ne-
gated the significance of a similar finding in their cohort, but did
note a correlation between age-adjusted blood heteroplasmy levels
and both HbA1C, levels and low BMI (Laloi-Michelin et al., 2009).
5.6. Pancreatic pathology
Mitochondrial dysfunction within the metabolically active pan-
creatic B-cells is presumed to account for reduced function and
ultimately loss of B-cell mass (Kobayashi et al., 1997; Lynn et al.,
2003). It has been difficult to demonstrate apoptosis (Kobayashi
et al., 1997) which is the presumed explanation for the surprisingly
low levels of heteroplasmy found in remaining B-cell tissue at au-
topsy (Togashi et al., 2000; Lynn et al., 2003). HLA polymorphisms
associated with type-1 susceptibility have not been found in mito-
chondrial diabetes (van Essen et al., 2000). Our own m.3243A > G
cohort do not, in general, carry islet cell or GAD antibodies (unpub-
lished data) but these have been found in a minority of patients by
other groups (Oka et al., 1993; Murphy et al., 2008). These cases
may represent coincidental autoimmune type-1 diabetes but it
has also been hypothesised that antibodies might be produced in
direct response to pancreatic B-cell destruction as a result of mito-
chondrial mechanisms (Oka et al., 1993). Acute or chronic pancre-
atitis is rarely described (Kishnani et al., 1996; Schleiffer et al.,
2000; Verny et al., 2008; Ishiyama et al., 2012).
5.7. Diabetes management
The majority of patients present with non-insulin dependent
diabetes. A sulphonylurea is the first agent of choice. Care must
be taken because some patients appear to be particularly sensitive
to sulphonylurea induced hypoglycaemia. For this reason, we fa-
vour sulphonylureas with a short half-life, and always start with
the very lowest dose and titrate up. Metformin is best avoided be-
cause of the risk of exacerbating lactic acidosis. Having said this,
we have used metformin in patients with accompanying obesity
and have not experienced any clinical problems. The emergence
of newer agents such as DDP4 inhibitors and GLP-1 analogues offer
alternative therapeutic opportunities, and we are using them as
second line treatment in preference to metformin depending upon
the clinical indications. As detailed above, a minority of patients re-
quire insulin from the time of diagnosis, and those with initial non-
insulin dependent diabetes often progress rapidly to insulin ther-
apy. We tailor the insulin regimen to patient’s individual lifestyle
and daily needs.
As described above, progression to end stage renal failure and
kidney transplantation is a recognised outcome. This opens up
the possibility of pancreas transplantation, either as a simulta-
neous kidney and pancreas procedure or as a pancreas after kidney
transplant. A key attraction is that there is no on-goingautoimmune process in mitochondrial diabetes (unlike patients
with type 1 diabetes undergoing transplantation), and so the trans-
planted organs in theory should last longer.
While discussing management it is worth clarifying the role of
statins in mitochondrial diabetes. Statins are often recommended
for diabetic patients to help lessen the risks of atherosclerotic com-
plications. Understandably, use of a drug with the potential to in-
duce a myositis often causes concern in relation to pre-existing
mitochondrial myopathy. In the majority of cases we do not be-
lieve the risks outweigh the benefits, but do advise caution. As
many patients with mitochondrial disease often have a mildly ele-
vated creatine kinase (CK < 1000IU) at baseline, we recommend
documentation of pre-treatment CK levels with repeat CK mea-
surements while on statin therapy and advise to report new myal-
gia or weakness.
It is evident that mitochondrial diabetes is complicated. The
disease pattern with a high risk of rapid progression to insulin
and the high prevalence of complications means that patients need
access to a specialist diabetes service offering regular review. The
situation is further complicated by the multisystem nature of mito-
chondrial disease. As a consequence, we have just recently estab-
lished a combined mitochondrial/diabetes clinic run jointly by
the neurologists and diabetologists that provides an integrated,
one-stop service for patients with mitochondrial diabetes. We have
also developed Best Practice Guidelines for mitochondrial diabetes
which are available online (http://www.newcastle-mitochon-
dria.com/service/patient-care-guidelines/).6. Hypoparathyroidism
Hypoparathyroidism is best described in KSS which occurs as a
result of a sporadic, single large-scale mtDNA rearrangement.
Although reports are relatively rare, they seem consistent (Quade
et al., 1992; Isotani et al., 1996; Katsanos et al., 2001; Cassandrini
et al., 2006; Wilichowski et al., 1997). In each case children have
multisystem disease, often with renal disease or other endocrinop-
athies in addition to the classic KSS phenotype. There does not ap-
pear to be an autoimmune basis to the hypoparathyroidoism
(Isotani et al., 1996). Autopsy studies suggest absent or atrophic
hypoparathyroid glands (Horwitz and Roessmann, 1978; Bordarier
et al., 1990). Although some patients with basal ganglia calcifica-
tion on CT have been found to have hypoparathyroidism (Seigel
et al., 1979; Cassandrini et al., 2006) the majority have no abnor-
malities of calcium homeostasis. The genetic basis of KSS was first
confirmed in 1988 (Holt et al., 1988) and reports of hypoparathy-
roidism (and other endocrinopathies) in KSS prior to that period
are unsupported by genetic studies ((Horwitz and Roessmann,
1978; Seigel et al., 1979; Dewhurst et al., 1986). It is possible that
some of these cases may have harboured mtDNA point mutations
(e.g. m.3243A > G) or multiple mtDNA deletions of a nuclear cause.
Harvey and Barnett’s (1992) review found 14 of 226 patients with
KSS and CPEO to have hypoparathyroidism, but the relevant mes-
sage from this study is probably more pertinent to endocrine dis-
ease associated with the phenotype than the genotype, as not all
cases had been genetically confirmed (Harvey and Barnett, 1992).
Hypoparathyroidism has been described in patients with ar-RRM2B
mutations, for example, and historically would have been included
in this group on the basis of the clinical features (Pitceathly et al.,
2012).
In our experience, hypoparathyroidism is extremely rare in
adult forms of mitochondrial disease. The paucity of case reports
in the literature suggests likewise (Tanaka et al., 2000). It seems
most likely to occur in very severely affected patients who present
in childhood with multisystem disease. This may suggest that clin-
ically significant levels of heteroplasmy within the parathyroid
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tion of the parathyroid glands, is only reached in cases where very
high levels of heteroplasmy are present in most tissues.
7. Hypothalamo-pituitary axis
The most consistent descriptions of endocrine dysfunction
due to impairment of the hypothalamopituitary axis appear to
be in severe mitochondrial phenotypes presenting in childhood.
MELAS and KSS appear the most common phenotypes. The endo-
crine disorder may precede the neurological features and lactic
acidosis is often the clue to a mitochondrial cause. Short stature
is usually present and more classical phenotypic expression
develops later if the patient survives. Reports in adults are much
rarer.
8. Growth hormone deficiency
Growth hormone (GH) deficiency has been described in KSS,
both before and after genetic testing became available (Harvey
and Barnett, 1992; Quade et al., 1992; Mohri et al., 1998; Berio
and Piazzi, 2000; Cassandrini et al., 2006; Berio and Piazzi, 2007).
It has also been reported in MELAS due to the m.3243A > G muta-
tion in children (Yorifuji et al., 1996; Robeck et al., 1996; Balestri
and Grosso, 2000; Matsuzaki et al., 2002) and in very rare adult
cases with the MELAS (Ishii et al., 1991) and MIDD phenotypes
(Joko et al., 1997). GH deficiency is often declared to be the cause
of short stature in the mitochondrial myopathies, but the causes
are more likely to be complex and multi-factorial for most patients
(Wolny et al., 2009). Publication bias is probably to blame for the
lack of reports documenting short stature and normal GH, but
these probably form the majority of cases.
9. Hypogonadism
Mutations in the POLG gene have been associated with primary
testicular failure (Filosto et al., 2003), primary ovarian failure (Luo-
ma et al., 2004; Hakonen et al., 2005), and ovarian dysgenesis (Bek-
heirnia et al., 2012). ar-PEO1 mutations are reported to cause
female hypergonadotrophic hypogonadism by teen age (Lönnqvist
et al., 2009). Hypogonadism has been reported in association with
mtDNA depletion due to ar-RRM2B mutations whilst cases of both
hypergonadotropic and hypogonadotropic hypogonadism have
been described in reports of mitochondrial neurogastrointestinal
encephalopathy (MNGIE) (Carod-Artal et al., 2007; Kalkan et al.,
2012). It has been suggested from review of the early literature
that up to 20% of patients with KSS develop gonadal dysfunction,
either before or after puberty (Harvey and Barnett, 1992; Quade
et al., 1992). Both sexes were affected equally. It is possible how-
ever that some of the patients diagnosed on clinical and histologi-
cal grounds alone may have carried other mtDNA mutations or AR
forms of disease rather than single deletions of the mtDNA. Genet-
ically-confirmed case reports exist but are rare (Barrientos et al.,
1997). Low levels of follicle stimulating hormone (FSH) and lutein-
izing hormaone (LH) have both been reported in MELAS (Ishii et al.,
1991; Robeck et al., 1996; Ohkoshi et al., 1998; Balestri and Grosso,
2000) but are also rare. In both KSS and MELAS it is possible that
hypogonadism is underdiagnosed where other forms of multisys-
tem disease dominate the clinical picture.
10. Hypothyroidism
Thyroid disease is not a recognised complication of mitochon-
drial disease. Observations from our own mitochondrial cohortare that it occurs in similar frequency to the background popula-
tion, and is often associated with thyroid antibodies as might be
expected. Reports in KSS are rare and usually associated with auto-
immunity (Berio and Piazzi, 2006; Sanaker et al., 2007); only rare
reports exist for patients with the m.3243A > G mutation (Balestri
and Grosso, 2000; Lau et al., 2007). Hypothyroidism was docu-
mented in 2/18 adult RRM2B patients, but antibody status was
not reported (Pitceathly et al., 2012).11. Hypoadrenalism
This is rarely described in mitochondrial disease but impor-
tantly has been reported in children prior to the development of
typical features of KSS. Patients are often neurologically normal
at presentation but have short stature and may exhibit a lactic aci-
dosis. Adrenocorticotropic hormone (ACTH) is elevated but anti-
bodies negative (Nicolino et al., 1997; Boles et al., 1998). We
have recently identified an adult harbouring a single, large-scale
mtDNA deletion and a mild KSS phenotype who developed non-
autoimmune adrenal insufficiency at 51 years of age (personal
observation).12. SIADH
The syndrome of inappropriate anti-diuretic hormone secretion
(SIADH) is probably under recognised as an endocrine disorder in
mitochondrial disease. Hyponatraemia may also occur as a result
of unrecognised renal disease, adrenal insufficiency, or gastrointes-
tinal losses related to pseudoileus, while in other cases the cause
may not be identified (Kubota et al., 2005; Gurrieri et al., 2001).
In our experience, hyponatraemia is relatively common in patients
carrying the m.3243A > G mutation, but not always due to SIADH.
When this occurs it is usually transient and associated with stroke-
like episodes and more specifically ongoing seizure activity (Patel
et al., 2007). In this respect SIADH can sometimes be an indication
of active cerebral dysfunction. MELAS patients appear prone to
SIADH, or exacerbation of pre-existing SIADH, with certain anti-
convulsants such as carbamazepine. In most cases this is not severe
enough to prevent the use of clinically useful drugs in the acute
setting, but may affect subsequent treatment choices.13. Adipose tissue as an endocrine organ
There has been very little work looking at adipose tissue func-
tion in mitochondrial diabetes. A recent study compared adipose
tissue and liver fat metabolism between patients with the
m.3243A > G mutation and healthy control subjects. They found
that patients with the mutation showed evidence of adipose tissue
insulin resistance and a tendency to increased liver fat. However,
as there were no diabetes controls, it was not clear to what extent
the metabolic changes reflect the diabetic state rather than specific
changes related to the mitochondrial disease (Lindroos et al.,
2011). Further work is needed to determine whether there are adi-
pose tissue abnormalities that are specific to mitochondrial
disease.
One such scenario occurs in Ekbom’s Syndrome. Originally de-
scribed as ‘hereditary ataxia, photomyoclonus, skeletal deformities
and lipoma’ (Ekbom, 1975), it was subsequently confirmed to oc-
cur as a result of the m.8344A > G MTTK mutation associated with
the MERRF phenotype (Träff et al., 1995). Many MERRF patients de-
velop unusual lipomata around the neck and shoulder region cor-
responding to the distribution of brown fat tissue; these lesions
may be painful, restrict movement, and account for major aesthetic
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this phenomenon are currently undetermined.14. Autoimmune endocrinopathy
Autoimmune endocrine disease has been reported in several
forms of mitochondrial disease. Despite this, overall there is a lack
of firm evidence to suggest autoimmune disorders are any more
prevalent in mitochondrial cohorts than in the general population.
Most cases of MIDD do not have anti-GAD or islet cell antibodies
but these have been reported in small numbers (Oka et al., 1993;
Murphy et al., 2008) and more frequently in some cohorts (Kobay-
ashi et al., 1996). It has been hypothesised that mitochondrial dys-
function may play some role in the development of autoimmunity
but this remains unproven. In diabetes, pancreatic B-cell destruc-
tion has been proposed as the catalyst for antibody production
(Oka et al., 1993).
Autoimmune hypothyroidism is described rarely in patients
with KSS, one such report also having Addison’s disease with adre-
nal antibodies (Berio and Piazzi, 2006; Sanaker et al., 2007).
Autoimmune polyglandular syndrome type II has been reported
once in a mild KSS/CPEO phenotype. The endocrine features were
Addison’s disease, IDDM, autoimmune thyroiditis and primary
ovarian failure. Interestingly this patient carried both a 2,532-bp
deletion of her mtDNA, consistent with KSS, but also a heteroplas-
mic m.3243A > G mutation which was also present in her mother’s
mtDNA. Whether mitochondrial disease played a role in this is un-
clear (Ohno et al., 1996).15. Conclusion
Endocrine dysfunction in mitochondrial disease is common,
but predominantly due to the prevalence of the m.3243A > G
mutation and its association with diabetes mellitus. Other
mtDNA mutations reliably expressing a diabetic phenotype are
rare, and other forms of endocrine dysfunction are unusual when
considering the mitochondrial diseases as a whole. Pattern rec-
ognition and detailed pedigee analysis are key when evaluating
the likelihood of a mitochondrial disorder, and the presence of
endocrine disease may contribute to the diagnostic process.
Furthermore, appreciation of the endocrine organs at risk in a
specified genotype/phenotype allows an appropriate level of
screening to be initiated as part of the patient’s multidisciplinary
care strategy. KSS patients are at risk of hypoparathyroidism, and
patients with advanced multi-system disease presenting in child-
hood, whether due to mtDNA mutations or nuclear mtDNA
maintenance genes, appear at risk of hypothalamopituitary dys-
function. Most patients with mitochondrial disease, but most
notably those carrying the m.3243A > G mutation, should have
access to annual screening for diabetes. The tendency to multi-
system disease in these complex families can make management
difficult, even in asymptomatic carriers. For this reason we rec-
ommend referral to a specialist mitochondrial centre for disease
specific advice and management plans.Acknowledgments
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